gas from tirzepatide Does Cause Bloating? Tirzepatide reduces food intake and

However, GLP-1 agonists primarily lead to weight loss by reducing appetite and caloric intake

Contrave uses a 4-week titration schedule specifically to minimize these early side effects

Survodutide, developed by Boehringer Ingelheim, is in Phase 3 development with a particular focus on metabolic-associated steatohepatitis (MASH) in addition to obesity

Note: The above is illustrative

Keywords: Pharmacokinetics, semaglutide, curve plasma concentrations, type 2 diabetes, obesity, glucagon-like peptide-1, drugdrug interaction Introduction Type 2 diabetes (T2D) and obesity are major public health burdens with an important economic impact and their incidences have increased in the past decades

Prescribing Information: Wegovy (semaglutide) tablets, for oral use